Subscribe
Strategy
4 min read

Mighty Paw's Walmart Launch Completes a Three-Brand Pattern in DTC Pet Treats

Mighty Paw placed its yak cheese chews and puffs into every Walmart store nationwide, becoming the third direct-to-consumer pet treat brand The Underbite has tracked crossing into mass retail since May. The release discloses no financial backer, store-door count, or revenue figure to frame the trade.

Written by
Roy Ben-Tzvi
Published on
August 4, 2026
Mighty Paw's Walmart Launch Completes a Three-Brand Pattern in DTC Pet Treats

For the third time since May, a small direct-to-consumer pet treat brand has traded its own margins for space on a mass retailer's shelf. Mighty Paw is the latest, putting its yak cheese chews and puffs into every Walmart store nationwide and joining a pattern The Underbite has now tracked across three separate brands in three months.

Mighty Paw's yak chews land in every Walmart

Mighty Paw announced on August 4th that its Yak Cheese Chews and Yak Cheese Puffs, limited-ingredient dog treats made from milk, lime juice, and salt, are now stocked nationwide at Walmart stores and on walmart.com. Chews start at $11.99, puffs at $13.99. The products remain available direct through mightypaw.com as well.

Founder Corey Smith started the company after searching for treats for his own dog, Barley, and the release states the products are trusted by more than 2 million dogs, without specifying whether that figure counts units sold, repeat customers, or another measure. "Launching at Walmart allows us to bring our premium, limited-ingredient treats to even more pet parents looking for simple, high-quality options they can trust," Smith said.

The release discloses no store-door count, no wholesale terms, and no timeline for how the Walmart relationship came together, details that would normally frame how big a step this actually is for a brand that built its base online.

A third brand makes the same margin trade

Mighty Paw is not the first small pet-treat brand to make this move this year. Three Dog Brands, a private-equity-backed maker of dog treats, placed a chicken-chip line into Walmart in May after a 23-month platform buildout. A Shark Tank-born water-bottle brand, Springland, crossed into Target in July, trading its direct margins for national shelf reach. Mighty Paw's Walmart placement makes it the third DTC pet brand The Underbite has tracked crossing into mass retail in three months, and the first among the three built entirely around a single treat category.

The pattern is now more instructive than any single instance of it. Each brand accepted the same tradeoff: wholesale pricing compresses per-unit margin and hands inventory forecasting to a retailer's category-management process, in exchange for shelf reach no online funnel can buy at the same cost. What differs is disclosure. Three Dog Brands' owner, Topspin Consumer Partners, has a documented manufacturing and bolt-on M&A strategy behind its Walmart placement. Springland disclosed roughly $2 million in annual revenue framing the stakes of its Target move. Mighty Paw's release names neither a financial backer nor a revenue figure, leaving operators unable to judge from the release alone whether this is a founder-funded brand betting its own cash flow on a retail transition or a lightly disclosed platform play.

The 2-million-dogs figure carries the same ambiguity. It could describe cumulative units sold, unique repeat customers, or a marketing estimate extrapolated from reviews and social following, and the release does not say which. That matters because the number is the only scale signal in the release. Without a defined basis, it functions as a marketing claim rather than the kind of operator-usable metric a store-door count or trailing revenue figure would provide.

Mighty Paw's three-ingredient positioning also rides a broader shift toward simplified, functional treats, the same instinct behind a European chew brand cutting prices while going clean-label, and the industry's wider move toward botanical antioxidants over synthetic preservatives. Retailers treating limited-ingredient formats as table stakes rather than a premium differentiator is part of why Walmart's buyers are receptive to brands like this one in the first place.

What separates a durable Walmart run from a fad

The next two quarters will show whether Mighty Paw's Walmart placement holds. Sell-through data, invisible to outside observers but closely watched by Walmart's category buyers, determines whether a treat SKU earns a planogram renewal or gets cut at the next reset. A second SKU or pack-size addition at Walmart within two quarters would signal the retailer sees room to grow the line, the same tell that preceded Three Dog Brands' own flavor extension within weeks of its Walmart placement.

Watch too for whether Mighty Paw discloses a financial backer. A founder-led brand absorbing wholesale margin compression on its own balance sheet carries different risk than one with private-equity capital behind the transition. And watch the DTC-to-mass pattern itself: three brands crossing in three months is enough to call a trend. A fourth would confirm that 2026 is the year small pet-treat brands stopped treating Walmart and Target as an endpoint and started treating them as a required second act.

Source: Mighty Paw via PR Newswire

Subscribe to newsletter

Join our newsletter to stay up to date on features and releases.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.

What's Happening

Other News

More stories shaping the pet industry this week. From funding rounds and product launches to regulatory shifts and retail strategy, stay ahead of what's driving the market.

Read article
GoodVets Buys WellHaven's 40 Hospitals, Ending Its De Novo-Only Era
Funding & M&A
5 min read

GoodVets Buys WellHaven's 40 Hospitals, Ending Its De Novo-Only Era

GoodVets is acquiring WellHaven Pet Health's network of more than 40 hospitals, growing its footprint from 75 to 116 locations. The deal marks a shift from the de novo strategy that defined the General Atlantic-backed platform's first decade toward the acquisition-led growth every other scaled vet consolidator already runs on.

Read article
Read article
Dechra's Oral Cancer Pill Targets the Dogs Chemo Never Reaches
Launches
5 min read

Dechra's Oral Cancer Pill Targets the Dogs Chemo Never Reaches

Dechra is commercially launching Laverdia, the first FDA-approved oral treatment for canine lymphoma, developed by Anivive and licensed to Dechra in 2022. The bet isn't on winning cases from oncology referral networks, but on treating the roughly 80% of diagnosed dogs who currently get no chemotherapy at all.

Read article
Read article
PetMeds Names New CEO, Rebuilds Board Amid Takeover Fight
People
5 min read

PetMeds Names New CEO, Rebuilds Board Amid Takeover Fight

PetMeds named Jeff Willard as its next CEO and added two new independent directors, including a Shake Shack executive as board chair, while a $3-a-share takeover bid from SilverCape Investments remains unanswered since June. None of the three new leaders has prior ties to the company, a signal the board is building outside credibility for whatever comes next.

Read article
View all articles